3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Melanoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Astrocytoma
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
Bevacizumab
26
Cetuximab
24
Fluorouracil
23
Leucovorin
22
Oxaliplatin
19
pembrolizumab
18
Specimen Handling
11
Irinotecan
10
Nivolumab
8
Magnetic Resonance Spectroscopy
8
atezolizumab
7
Biopsy
7
Pemetrexed
6
Panitumumab
6
Cisplatin
6
Carboplatin
6
trifluridine tipiracil drug combination
5
fludarabine
5
encorafenib
5
HMPL-013
5
Gemcitabine
5
Folfox protocol
5
Standard of Care
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
zanidatamab
3
regorafenib
3
fludarabine phosphate
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
ribociclib
×
30 days
×
Clear all
NCT05358249
2026-06-15
KontRASt-03
Novartis
Phase 1/2
Active not recruiting
74 enrolled